Delft: Universities that filed detailed submissions to Brussels in January are still waiting to see what any of it produced. The ERA Act, the Commission’s attempt to give the European Research Area a legal spine after two decades of voluntary coordination, was promised for the third quarter of this year. The quarter has a fortnight left.
The consultation itself drew an unusually engaged response. Seven hundred and thirty-five contributions arrived, together with one hundred and seventeen position papers, from every member state, eight countries associated to Horizon Europe and fifteen others. Research organisations do not usually mobilise at that scale for a framework instrument, and the volume tells you what the sector expects: enforceable commitments rather than another communication.
What the ERA Act is meant to fix has been documented for years. Researchers moving between member states lose pension rights and social security continuity. National funders run incompatible application systems. Research infrastructures built with EU money operate under twenty-seven access regimes. The three percent of GDP research spending target, first set in Lisbon in 2000, has never been met by the Union as a whole and several capitals have stopped pretending they will reach it.
Commissioner Ekaterina Zaharieva has described her ambition as realistic, which the sector reads as a signal that hard obligations on national budgets will not appear. The likely architecture places binding elements where the Union has clear competence, meaning mobility, open access and the governance of shared infrastructures, while leaving investment levels to a reinforced coordination mechanism with reporting duties attached. That produces a law that improves the plumbing without touching the money.
Rectors and national academies argue that plumbing is the point. A doctoral researcher who moves from Portugal to Finland and back currently loses more in accrued entitlements than most mobility grants provide, and no amount of extra funding fixes a portability problem. Fragmented ethics review delays multi-country clinical studies by months. These are legislative failures rather than budgetary ones, and a directive can address them.
Timing has become the sharper worry. The ERA Act will land in the middle of negotiations on the next multiannual budget, where research funding faces its own contested arithmetic, and in a Parliament whose research committee is already carrying the Innovation Act. A proposal published in October competes for attention with files that have deadlines attached. A proposal that slips into next year risks arriving after the budget numbers are settled, which would strip it of leverage over exactly the investment commitments the sector wants.
The Commission maintains that the third-quarter target still holds and publishes progress on the European Research Area platform. Officials point out that an analysis of the call for evidence appeared earlier this year and that inter-service consultation is under way. Researchers have watched enough legislative timetables to discount that reassurance without dismissing it.
Whatever arrives will take at least two years to pass through Parliament and Council, and several more to transpose. A postdoctoral researcher choosing between Leiden and Lausanne this autumn will have finished two contracts before the ERA Act changes anything about that choice. The gap between the diagnosis and the remedy is the criticism the Commission will find hardest to answer.
